February 8, 2010
Repros Submits Response to FDA Regarding Androxal® Indication for Treatment of Hypogonadal Men Wishing to Preserve Fertility
February 2, 2010
Repros' New IND for the Investigation of Androxal® in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
January 27, 2009
Repros Receives Guidance from FDA Regarding Continued Development of Androxal® in Hypogonadal Men
January 15, 2010
Repros Approved for Trading on Nasdaq Capital Market
January 11, 2010
Repros Shelf Registrations of Stock Are Effective
